Is Peppermint Gut Motility Meta-Analysis safe?

Updated July 2026

Quick Answer

Peppermint Gut Motility Meta-Analysis has evidence relevant to safety, limits, and clinician-discussion contexts, but conclusions should stay close to the cited sources. One representative finding is: Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades [].

Key Takeaways

  • 01Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades []. [Pastras Ploutarchos (2026)]
  • 02More specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form []. [Pastras Ploutarchos (2026)]
  • 03IBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden []. [Pastras Ploutarchos (2026)]
  • 041 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain []. [Pastras Ploutarchos (2026)]
The current Migaku evidence database contains 2 reusable source documents for Peppermint Gut Motility Meta-Analysis. This answer focuses on safety, limits, and clinician-discussion contexts. - Young adults, particularly females, have a higher prevalence, which has increased substantially over the past decades []. [Pastras Ploutarchos (2026); evidence level 2] - More specifically, the presence of recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: symptoms related to defecation, a change in stool frequency, or a change in stool form []. [Pastras Ploutarchos (2026); evidence level 2] - IBS is associated with reduced engagement in daily activities, increased work absenteeism, and impaired functioning, thereby increasing the global healthcare burden []. [Pastras Ploutarchos (2026); evidence level 2] - 1 2 1 3 1 4 5 Disorders of gut–brain interaction (DGBIs) are functional gastrointestinal conditions characterized by a complex interplay between the gut and the brain []. [Pastras Ploutarchos (2026); evidence level 2] - 1 2 3 4 5 5 6 7 6 7 Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction characterized by recurrent abdominal pain associated with altered bowel habits, in the absence of identifiable structural abnormalities []. [Šuran Jelena (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Plant-Derived Treatments for IBS: Clinical Outcomes, Mechanistic Insights, and Their Position in International Guidelines
  2. IBS and SIBO: Gut Microbiota, Pathophysiology, and Non-Pharmacological Interventions